Vilazodone for the treatment of major depressive disorder.
Iranikhah M, Wensel TM, Thomason AR.
Pharmacotherapy · journal article · DOI 10.1002/j.1875-9114.2012.01121 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för vilazodone. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
21 träffarEvidence for the use of vilazodone in the treatment of major depressive disorder.
Reinhold JA, Mandos LA, Lohoff FW, Rickels K.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2012.721776Vilazodone: a novel antidepressant.
Choi E, Zmarlicka M, Ehret MJ.
Am J Health Syst Pharm · review; journal article · DOI 10.2146/ajhp110374Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use.
Singh M, Schwartz TL.
Neuropsychiatr Dis Treat · review-article; journal article · DOI 10.2147/ndt.s20683Emerging drugs for major depressive disorder.
Connolly KR, Thase ME.
Expert Opin Emerg Drugs · review; journal article · DOI 10.1517/14728214.2012.660146Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L.
Int J Clin Pract · systematic review; journal article · DOI 10.1111/j.1742-1241.2011.02885.xClinically significant drug interactions with newer antidepressants.
Spina E, Trifirò G, Caraci F.
CNS Drugs · review; journal article · DOI 10.2165/11594710-000000000-00000Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.
Mandrioli R, Mercolini L, Saracino MA, Raggi MA.
Curr Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.2174/092986712800099749The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, Thase ME.
Curr Med Res Opin · comparative study; research support, non-u.s. gov't; evaluation study; journal article · DOI 10.1185/03007995.2011.628303A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder.
Robinson DS, Kajdasz DK, Gallipoli S, Whalen H, Wamil A, Reed CR.
J Clin Psychopharmacol · clinical trial; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1097/jcp.0b013e31822c6741ACS chemical neuroscience molecule spotlight on viibryd (Vilazodone).
Hopkins CR.
ACS Chem Neurosci · editorial; review; journal article · DOI 10.1021/cn200084vVilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant.
Laughren TP, Gobburu J, Temple RJ, Unger EF, Bhattaram A, Dinh PV, Fossom L, Hung HM, Klimek V, Lee JE, Levin RL, Lindberg CY, Mathis M, Rosloff BN, Wang SJ, Wang Y, Yang P, Yu B, Zhang H, Zhang L, Zineh I.
J Clin Psychiatry · review; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.4088/jcp.11r06984Vilazodone: in major depressive disorder.
Frampton JE.
CNS Drugs · review; journal article · DOI 10.2165/11207550-000000000-00000Vilazodone (Viibryd)--a new antidepressant.
Författaruppgift saknas
Med Lett Drugs Ther · review; journal articleVilazodone: a new treatment option for major depressive disorder.
Owen RT.
Drugs Today (Barc) · journal article · DOI 10.1358/dot.2011.47.7.1622076Vilazodone for the treatment of depression.
Lindsey WT.
Ann Pharmacother · review; journal article · DOI 10.1345/aph.1p772A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, Reed CR.
J Clin Psychiatry · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.4088/jcp.10m06596Vilazodone: another novel atypical antidepressant drug.
Howland RH.
J Psychosoc Nurs Ment Health Serv · journal article · DOI 10.3928/02793695-20110203-98Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression.
Khan A.
Expert Opin Investig Drugs · research support, non-u.s. gov't; review; journal article · DOI 10.1517/13543780903286396Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR.
J Clin Psychiatry · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.4088/jcp.08m04637Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.
Dawson LA, Watson JM.
CNS Neurosci Ther · research-article; review; journal article · DOI 10.1111/j.1755-5949.2008.00067.x